The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
A Luminex Approach to Develop an Anti-Tumor-Associated Antigen Autoantibody Panel for the Detection of Prostate Cancer in Racially/Ethnically Diverse Populations
Open accessAbstract
(1) Background: Autoantibodies to tumor-associated antigens (TAAs) have emerged as promising cancer biomarkers. Luminex technology offers a powerful approach for the simultaneous detection of multiple anti-TAA autoantibodies. (2) Methods: We aimed to utilize Luminex technology to evaluate and optimize a panel of anti-TAAs autoantibodies for detecting prostate cancer (PCa), which included autoantibodies to fourteen TAAs. A total of 163 serum samples (91 PCa, 72 normal controls) were screened to determine the levels of the autoantibodies using the Luminex assay. (3) Results: Twelve autoantibodies exhibited significantly high frequencies ranging from 19.8% to 51.6% in the PCa group. Receiver operating characteristic (ROC) curve analysis revealed area under the curve (AUC) values ranging from 0.609 to 0.868 for the twelve autoantibodies individually. We further confirmed the performance of the HSP60 autoantibody by using an enzyme-linked immunosorbent assay (ELISA) in a larger sample comprising 200 PCa sera, 20 benign prostatic hyperplasia (BPH) sera, and 137 normal control sera. The results obtained from the Luminex assay were consistent with the ELISA findings. We developed a panel consisting of three autoantibodies (p16, IMP2, and HSP60) which achieved an impressive AUC of 0.910 with a sensitivity of 71.4% and a specificity of 95.8%. The panel was also evaluated in PCa patients from different races/ethnicities with the best performance observed in distinguishing the Hispanic American patients with PCa from normal controls. (4) Conclusions: We developed an anti-TAA autoantibody panel for the detection of PCa that exhibits promising performance. This panel holds significant potential as a high-throughput tool to facilitate PCa detection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
p53 Antibodies in the sera of patients with various types of cancer: a review.
Soussi, T. (2000) · PubMed · Cited by 643
duPont, N. C., Wang, K., Wadhwa, P. D., Culhane, J. F., & Nelson, E. L. (2005) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2005.03.005 · Cited by 318
Autoantibodies to tumor‐associated antigens: reporters from the immune system
Tan, E. M., & Zhang, J. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00611.x · Cited by 309
Self-citationThe role of heat shock proteins in cancer
Lianos, G. D., Alexiou, G. A., Mangano, A., Mangano, A., Rausei, S., Boni, L., Dionigi, G., & Roukos, D. H. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.02.026 · Cited by 308
Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens.
Zhang, J.-Y., Casiano, C. A., Peng, X.-X., Koziol, J. A., Chan, E. K. L., & Tan, E. M. (2003) · PubMed · Cited by 270
Self-citationClinical validation of an autoantibody test for lung cancer
Boyle, P., Chapman, C. J., Holdenrieder, S., Murray, A., Robertson, C., Wood, W. C., Maddison, P., Healey, G., Fairley, G. H., Barnes, A. C., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq361 · Cited by 240
Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia
Lee, K. E., Spata, M., Bayne, L. J., Buza, E. L., Durham, A. C., Allman, D., Vonderheide, R. H., & Simon, M. C. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0822 · Cited by 227
Merriel, S. W. D., Pocock, L., Gilbert, E., Creavin, S., Walter, F. M., Spencer, A., & Hamilton, W. (2022) · BMC Medicine · doi:10.1186/s12916-021-02230-y · Cited by 214
A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges
Kohaar, I., Petrovics, G., & Srivastava, S. K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081813 · Cited by 173
Cited by
A tumor-binding antibody with cross-reactivity to viral antigens
Campa, M. J., Gottlin, E. B., Wiehe, K. J., & Patz, E. F. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-03975-8 · Cited by 10
Shin, D. W., Cho, J., Cho, S., Youn, Y., & Hwang, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-19631-1 · Cited by 5
IMPlications of IMP2 in RNA Biology and Disease
Das, J., Busia-Bourdain, O., Khan, K. M., & Wolfe, A. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062415 · Cited by 3
“IGF2BP2 mRNA and protein are frequently overexpressed across a wide variety of cancer types, as exemplified by proposals for IMP2 expression to be used as a predictive biomarker in prostate cancer as part of a panel of tumor-associated antigens [80].”
Kumar, E. P., Rahaman, H., Reddy, C. V., Sahil, R., Buchanalli, S., & Depuru, B. K. (2024) · International Journal of Innovative Science and Research Technology (IJISRT) · doi:10.38124/ijisrt/ijisrt24jun1368 · Cited by 3
Qiu, C., Wang, X., Francia, G., Casiano, C. A., & Zhang, J. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03242-8 · Cited by 2
Self-citation
Metadata
- Authors
- Qiu, C., Wang, X., Batson, S. A., Wang, B., Casiano, C. A., Francia, G., & Zhang, J.-Y.
- Affiliations
- The University of Texas at El Paso (US)
- Loma Linda University (US)
- Department of Biological Sciences & NIH-Sponsored Border Biomedical Research Center, The University of Texas at El Paso, El Paso, TX 79968, USA
- Corresponding author
- Francia, Giulio
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2023-08-11
- Volume
- 15
- Issue
- 16
- Pages
- 4064
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC10452333
- OpenAlex
- W4385760156
- Cited by
- 9
- References
- 46
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 1
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institutes on Minority Health and Health Disparities (NIMHD) (5U54MD007592, 1R21CA280647)
- NIH/National Cancer Institute (5U54MD007592, 1R21CA280647)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced Biosensing Techniques and Applications
- Keywords
- prostate cancer, tumor-associated antigens, autoantibodies, Luminex multiplex assay, autoantibody panel, HSP60, p16, IGF2BP2, tumor markers, racial and ethnic diversity, benign prostatic hyperplasia, cancer detection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Luminex Approach to Develop an Anti-Tumor-Associated Antigen Autoantibody Panel for the Detection of Prostate Cancer in Racially/Ethnically Diverse Populations. https://app.cochat.ai/papers/10.3390/cancers15164064
- The paper
- Qiu, C., Wang, X., Batson, S. A., Wang, B., Casiano, C. A., Francia, G., & Zhang, J.-Y. (2023). A Luminex Approach to Develop an Anti-Tumor-Associated Antigen Autoantibody Panel for the Detection of Prostate Cancer in Racially/Ethnically Diverse Populations. Cancers. https://doi.org/10.3390/cancers15164064
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.